Home
NewsNewsFertility care leader IVI RMA North America announces a new partnership with Island Reproductive Services
A leader in fertility care as well as assisted reproduction, IVI RMA North America has, on December 01, 2025, announced that it has finalized a new collaboration along with Island Reproductive Services – IRS which is the only reproductive medicine provider on Staten Island that has a fertility lab and also offers complete fertility treatment to its patients. Dr. Eric Knochenhauer, as well as Dr. Michael Traub, who are the partners of the company, are going to retain an equity stake within the business and also continue serving the patients.
The acquisition goes on to mark the entrance of IVI RMA North America into the New York City market and also adds two clinics of the Island Reproductive Services to IVI RMA North America’s ever-growing footprint comprising 25 labs as well as 70 satellites throughout the U.S. Apart from the clinics, 29 employees of the IRS are going to become part of IVI RMA North America. The company, along with it, also brings a full-service third-party reproduction program, which goes on to include the donor oocytes and embryos as well as gestational carriers, along with over 40 years of experience as well as compassionate IVF nurses. The business is going to continue to function as per its present brand for the time to come, at least.
As per the CEO of IVI RMA North America, Lynn Mason, they are indeed very excited so as to welcome Island Reproductive Services into the IVI RMA family. Doctors Knochenhauer as well as Traub have gone on to build a tremendous practice over almost 25 years, and they are honored to have them as their partners as they usher the presence of IVI RMA into New York City for the very first time.
It is well to be noted that the main clinic of IRS is located around 45 minutes from IVI RMA North America’s headquarters at Basking Ridge, N.J., offering patients of that clinic as well as the surrounding area much greater alternatives and convenience when it comes to the treatment.
According to Dr. Knochenhauer, they could not imagine a better partner than IVI RMA so as to take Island Reproductive Services to another level. He added that having a close connection to industry-leading research and scientific leadership, as well as the lab operations expertise of IVI RMA, is going to make sure that they continue to deliver the highest standards in care quality to patients from New York City and even beyond as they grow.
Besides the value on the clinical side of the business, onboarding the electronic medical records software of the IVI RMA and also getting access to top talent will enable them to enhance the complete patient experience, said Dr. Traub. They are indeed very proud to enter this new chapter, which is a part of the largest assisted reproductive group throughout the world.
Notably, the partnership with Island Reproductive Services goes on to highlight a shared commitment when it comes to compassionate and patient-centered care as well as continued investment in terms of clinical excellence.
Chief Medical Officer of IVI RMA North America, Dr. Thomas Molinaro, says that Island Reproductive Services is known for its continuous delivery in terms of excellent care along with outstanding clinical outcomes, and adding such fertility professionals and clinics, which are highly respected, to the IVI RMA family offers them the opportunity to roll out fertility care across New York City, which in every way is outstanding.
The AI-specialized Infertility Center, which is the largest in Asia, is open in Magok, Seoul and has begun its full-scale medical services from November 17 thereby marking the new era when it comes to fertility in the region.
Alife Health secured CE Mark approval for its AI-powered embryo selection tool, Embryo Predict, under EU MDR, expanding its fertility technology presence across Europe.
Simbryo Technologies introduces the Simbryo FX personalized assay, a diagnostic test that measures endometrial fertility to predict embryo implantation success and improve IVF outcomes with more than 90% specificity.
South Korean couples travel abroad for gender-selective IVF procedures, spending dollars in Thailand and Cyprus due to domestic legal restrictions on choosing a baby's sex.
As more families pursue fertility treatments, IVF CRYO urges greater transparency and safety in better Safe Embryos and Eggs Shipping across the U.S.
China sees a rise in advanced maternal age In Vitro Fertilization, driven by BaseCare Medical’s AI undisturbed culture system that improves embryo quality and clinical pregnancy rates, especially with PGT. Localized AI-assisted solutions position BaseCare as a leader in smart, precision reproduction technology for older IVF patients.
According to a landmark large-scale IVF trial, using natural ovulation for frozen embryo transfers achieves matching birth rates to standard hormone cycles, offering a safer alternative for women.
